Zap-X Radiosurgery System Clinical Experience Report

This document is a clinical report detailing the initial experience with the ZAP-X Gyroscopic Radiosurgery System in treating recurrent intracranial lesions following Gamma Knife therapy. The study included six patients with various types of tumors who were treated between April and August 2023. The primary endpoint was the progression control rate at six months, while secondary endpoints included target lesion reduction and treatment effects based on tumor doubling time. Results indicated a 100% progression control rate at six months, with two patients showing partial responses and four maintaining stable disease. Adverse events were minimal, limited to imaging changes in one patient. The report emphasizes the potential of ZAP-X as a viable treatment option for patients with recurrent tumors after previous radiotherapy. The findings suggest a significant correlation between pre-treatment tumor doubling time and post-treatment reduction rates, highlighting the need for further studies to validate these results and assess long-term outcomes.